Details for Patent: 9,169,214
Which drugs does patent 9,169,214 protect, and when does it expire?
Patent 9,169,214 protects ATTRUBY and is included in one NDA.
This patent has twenty-three patent family members in eighteen countries.
Summary for Patent: 9,169,214
| Title: | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| Abstract: | Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein. |
| Inventor(s): | Isabella A. Graef, Mamoun M. Alhamadsheh |
| Assignee: | Leland Stanford Junior University |
| Application Number: | US13/830,731 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,169,214
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bridgebio Pharma | ATTRUBY | acoramidis hydrochloride | TABLET;ORAL | 216540-001 | Nov 22, 2024 | RX | Yes | Yes | 9,169,214 | ⤷ Start Trial | Y | TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,169,214
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2934514 | ⤷ Start Trial | 301323 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2934514 | ⤷ Start Trial | C20250016 | Finland | ⤷ Start Trial |
| European Patent Office | 2934514 | ⤷ Start Trial | CA 2025 00013 | Denmark | ⤷ Start Trial |
| European Patent Office | 2934514 | ⤷ Start Trial | PA2025512 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2934514 | ⤷ Start Trial | CR 2025 00013 | Denmark | ⤷ Start Trial |
| European Patent Office | 2934514 | ⤷ Start Trial | LUC50002 | Luxembourg | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
